Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-621 in healthy volunteers
NCT06673667Phase 1Completed
- Sponsor
- Kymera Therapeutics
- Start
- Oct 2024
- Primary completion
- Apr 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing KT-621 with Placebo (2 arms). Primary endpoints: Adverse Events at 38 days, Hematology Laboratory Parameters at 38 days and 7 more. Started Oct 2024; status: completed.
02
Drugs
KT-621
Beyond the preview
Go deeper on NCT06673667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673667.